For decades, scientists warned of the potential for a global coronavirus outbreak. But when SARS-CoV-2 emerged, no therapeutics, drugs or vaccines were readily available.
Founded by researchers at UNC-Chapel Hill, the Rapidly Emerging Antiviral Drug Development Initiative (READDI) is finding solutions to the COVID-19 pandemic while developing drugs and therapeutics for future viral outbreaks — so that next time, we'll be better prepared.
Join Tar Heels Together for an important conversation with campus experts including Eshelman Institute for Innovation Director John Bamforth and UNC School of Medicine Associate Professor Nat Moorman. They will discuss how READDI is bringing together the world’s best minds in science and business to proactively develop and deliver novel antiviral drugs before the next virus creates another global catastrophe.